Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 730,803 | 442,934 | 399,356 | 611,091 | 744,856 |
| Cost of Goods | 108,768 | 398,708 | 150,775 | 152,558 | 137,564 |
| Gross Profit | 622,035 | 44,226 | 248,581 | 458,533 | 607,292 |
| Operating Expenses | 264,370 | 456,517 | 352,745 | 343,514 | 908,242 |
| Operating Income | 358,433 | -411,583 | -103,389 | 115,577 | -300,386 |
| Other Income | -15,259 | 133,287 | -90,660 | 38,061 | -83,132 |
| Pre-tax Income | 343,174 | -278,296 | -194,049 | 153,638 | -383,518 |
| Income Tax | 12,215 | 4,551 | -14,102 | -43,254 | 63,990 |
| Net Income Continuous | 330,959 | -282,847 | -179,947 | 196,892 | -447,508 |
| Net Income | $330,959 | $-282,847 | $-179,947 | $196,892 | $-447,508 |
| EPS Basic Total Ops | 3.15 | -2.74 | -1.80 | 2.01 | -4.60 |
| EPS Basic Continuous Ops | 3.15 | -2.74 | -1.80 | 2.01 | -4.60 |
| EPS Diluted Total Ops | 2.88 | -2.62 | -1.80 | 1.89 | -4.60 |
| EPS Diluted Continuous Ops | 2.71 | -2.58 | -1.80 | 1.85 | -4.60 |
| EPS Diluted Before Non-Recurring Items | N/A | -3.87 | -0.28 | 1.70 | -3.84 |
| EBITDA(a) | $368,497 | $-406,710 | $-86,072 | $124,551 | $-292,320 |